Pfizer raises estimates for 2021 sales of COVID-19 vaccine to $33.5 bln

Reuters2021-07-28

July 28 (Reuters) - Pfizer Inc on Wednesday raised its forecast for sales of the COVID-19 vaccine that it developed with Germany's BioNTech by 28.8% to $33.5 billion, as countries scramble to secure supply of the shots.

The company said the raised sales forecast of the vaccine is based on signed deals for 2.1 billion doses this year.

The drugmaker's previous forecast in May of $26 billion was based on deals signed for 1.6 billion doses. Wall Street analysts were broadly in line with that forecast at $28.51 billion, according to nine analysts polled by Refinitiv.

Since then, Pfizer has said it expects to produce as much as 3 billion doses this year.

Expenses and profit from the vaccine are split 50-50 between Pfizer and BioNTech.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

  • Superstar_L
    2021-07-30
    Superstar_L
    Good 
  • Kencom
    2021-07-30
    Kencom
    The higher the demand, profitability will follow suit.
  • OPP
    2021-07-29
    OPP
    More and more to come with increasing confidence in it’s vaccine 
  • TrillionDM
    2021-07-29
    TrillionDM
    Really
  • Jazling
    2021-07-28
    Jazling
    Wow
  • Hibiki Anne
    2021-07-28
    Hibiki Anne
    good sharing
Leave a comment
19